New hires:

Teva appointed Matthew Shields as EVP of Teva Global Operations, effective June 3.

Zara Baker was named medical marketing agency Vue Health’s chief digital innovation officer.

JPA Health named Peter DeLorenzo as EVP of digital innovation.

Heller Agency welcomed Brian Peters as chief strategy and insights officer.

Zapata AI hired Sumit Kapur as CFO.

5W Public Relations named Michael O’Brien as global CEO, following the departure of co-chief executive Dara Busch.

Genomic medicines company Ensoma named Jim Burns, PhD as CEO.

Senhwa Biosciences hired Jason Huang, MD as chief medical officer.

Medication management technology company IntelliGuard appointed Rob Sobie as chief product officer.

Crowe PR announced three new hires: Jamie Avalon, Veronica Correa and Alana Pulver.

Executive elevations:

Crowe PR also recently promoted four team members.

Peloton Interactive promoted Letena Lindsay to global comms head.

R/GA brought together its U.S. and Latin American operations under the purview of April Quinn.

Board appointments:

Jennifer Schneider, MD, MS was elected to Vertex Pharmaceuticals’ board of directors.

Clinical-stage immuno-oncology company Nouscom named Dr. Gallagher, president of research and development at Syndax Pharmaceuticals and former chief medical officer and head of development at AbbVie, as independent advisor to its board of directors and chair of its R&D committee.

ReCode Therapeutics tabbed Dean J. Mitchell as chairman of the board of directors.

Clinical-stage gene therapy company Genprex named Jose A. Moreno Toscano as chairman of the board of directors.

Spyre Therapeutics appointed Dr. Sandra Milligan to its board of directors.

Avidity Biosciences named Simona Skerjanec to its board of directors.

Osmol Therapeutics added Christopher S. Eklund to its board of directors.

Intensity Therapeutics appointed Thomas Dubin to its board of directors.

Infinimmune named Dr. Neela Patel to its board of directors.


Eli Lilly announced that Alonzo Weems, EVP of enterprise risk management and chief ethics and compliance officer, as well as a member of the company’s executive committee, will retire at the end of the year. 

He will continue to serve in his role while Lilly conducts an internal and external search for a permanent chief ethics and compliance officer successor.

ATAI Life Sciences announced Florian Brand will transition from his role as CEO and serve as co-CEO with Dr. Srinivas Rao until the end of 2024. Then, Brand will step down and Rao will succeed him as sole CEO.

Acelyrin announced that Shao-Lee Lin is stepping down as CEO.

TikTok VP of global communications Hilary McQuaide announced she is leaving the video-based platform after seven years.

Takeda announced that Olivier Bohuon, an external director on its board of directors, passed away on May 5.


WPP CEO Mark Read was targeted by deepfake scammers.

Rick Slayman, the first man to receive a kidney transplant from a genetically engineered pig, died at 62.

See last week’s edition of The Escalator.